[1]郭伟伟,刘莉,吴德华.DC-CIK细胞免疫治疗联合TACE术治疗原发性肝癌[J].南方医科大学学报,2014,(05):674.
点击复制

DC-CIK细胞免疫治疗联合TACE术治疗原发性肝癌()
分享到:

《南方医科大学学报》[ISSN:/CN:]

卷:
期数:
2014年05期
页码:
674
栏目:
出版日期:
2014-05-15

文章信息/Info

Title:
Dendritic cell-cytokine induced killer cell immunotherapy combined with transcatheter
arterial chemoembolization for hepatocellular carcinoma: safety and efficacy
作者:
郭伟伟刘莉吴德华
关键词:
原发性肝癌肝动脉化疗栓塞细胞免疫治疗树突状细胞-细胞因子诱导的杀伤细胞
Keywords:
hepatocellular carcinoma transcatheter arterial chemoembolization immunotherapy dendritic cells-cytokineinduced killer cells
摘要:
目的探讨树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)免疫治疗联合TACE术在原发性肝癌中的临床疗效。方法回
顾性分析从2010年4月~2013年4月间在本院确诊并行TACE术的68例原发性肝癌患者,按是否联合DC-CIK治疗分为联合治
疗组(30例)和对照组(38例),对比分析治疗后两组患者无进展生存期、总生存期、生活质量改善、DC-CIK细胞治疗安全性等指
标。结果治疗组的中位无进展生存期为16个月,而对照组则为7个月,对比有统计学意义(P=0.033);治疗组的中位总生存期
为24个月,对照组为13个月,治疗组的1年生存率为80%,对照组则为75.2%,但两组对比无统计学意义(P=0.089);多因素分析
提示BCLC分期、治疗前AFP水平是影响无进展生存期的独立预后因素;而BCLC分期是影响总生存期的独立预后因素。治疗
组患者生活质量改善10例(33.3%)对比对照组4例(10.5%),差异有统计学意义(P=0.034);CIK治疗组治疗后仅有3例患者出
现发烧、1例出现过敏反应,对症处理后均恢复正常。结论DC-CIK细胞免疫治疗联合TACE术相比单纯TACE术,有助于延长
患者的无进展生存期,但在总生存期方面两组无统计学差异。此外,联合治疗能改善中晚期肝癌患者的生存质量,且治疗安全
可靠。
Abstract:
Objective To explore the clinical efficacy of dendritic cell-cytokine induced killer cell (DC-CIK) immunotherapy
combined with transcatheter arterial chemoembolization (TACE) for treatment of hepatocellular carcinoma. Methods Thirty
patients with hepatocellular carcinoma treated with TACE combined with DC-CIK cell therapy and 38 patients treated with
TACE alone (control group) were compared for progression-free survival time, overall survival time, quality of life, and
treatment-related adverse events. Results The median progression-free survival was 16 months in the combined treatment
group as compared with 7 months in the control group (P=0.033). The median overall survival time was 24 months in the
combined treatment group and 13 months in the control group, with 1-year overall survival rates of 80% and 75.2% ,
respectively, showing no significant differences between the two groups (P=0.089). Multivariate analysis indicated that
Barcelona-Clinic-Liver-Cancer (BCLC) staging and AFP level before treatment were two independent risk factors of
progression-free survival time, and BCLC stage served also as an independent risk factor of the overall survival time. Ten
patients in the combined treatment group (33.3%) showed improved quality of life, as compared with 4 patients (10.5%) in the
control group (P=0.034). Three patients receiving DC-CIK treatment experienced fever and 1 had allergic reaction, and the
symptoms remitted after expectant treatment. Conclusion Compared with TACE alone, DC-CIK immunotherapy combined
with TACE can improve the patients’ progression-free survival time but not the overall survival time. The combined therapy
also improves the quality of life of the patients with advanced hepatocellular carcinoma and shows good treatment safety.

相似文献/References:

[1]陈丽,石燕,蒋成英,等.瘦素和瘦素受体在肝癌中的表达与临床意义[J].南方医科大学学报,2011,(05):830.
[2]黄达仁,左强,蔡红兵,等.组织多肽特异性抗原在原发性肝癌中的临床应用[J].南方医科大学学报,2005,(01):89.
 HUANG Da-ren,ZUO Qiang,CAI Hong-bing,et al.Clinical value of serum tissue polypeptide specific antigen detection for primary hepatic cancer[J].,2005,(05):89.
[3]郑瑞丹,杨铮,饶日春,等.酷似原发性肝癌的肝巨大血管瘤1例报告[J].南方医科大学学报,2004,(03):342.
[4]薛净,李瑜元,聂玉强,等.高强度聚焦超声治疗原发性肝癌104例临床分析[J].南方医科大学学报,2006,(11):1675.
[5]贺松其,程旸,朱云,等.鳖甲煎丸对肝细胞癌中Wnt/β-catenin信号通路及抑制基因DKK-1、FrpHe表达的影响[J].南方医科大学学报,2013,(01):30.
[6]方姝煜,崔洁洁,龚梦嘉,等.全反式维甲酸诱导肝癌细胞Hepa1-6成熟和分化过程中的自噬[J].南方医科大学学报,2018,(05):527.

更新日期/Last Update: 1900-01-01